BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 215.3 EUR | +0.23% |
|
+5.54% | -8.30% |
| 05-16 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
| 05-16 | Sector Update: Health Care Stocks Ease Thursday Afternoon | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- With an enterprise value anticipated at 3.83 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.30% | 34.26B | - | ||
| -2.35% | 91.42B | A- | ||
| +3.16% | 41.08B | A- | ||
| +53.99% | 25.27B | A | ||
| -9.41% | 12.81B | B- | ||
| -12.25% | 11.6B | D+ | ||
| -44.00% | 11.42B | B | ||
| +5.77% | 9.16B | B+ | ||
| -5.03% | 8.22B | B- | ||
| -7.11% | 7.06B | D+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BIIB Stock
- IDP Stock
- Ratings Biogen Inc.
